Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B. Ribrag V, et al. Among authors: hayat a. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):309-317.e3. doi: 10.1016/j.clml.2020.12.012. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33632668 Free article. Clinical Trial.
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N, O'Brien D, Quinn FM, Smyth L, Kelly J, Parker I, Scott K, Cahill MR, Crotty G, Enright H, Hennessy B, Hodgson A, Leahy M, O'Leary H, O'Dwyer M, Hayat A, Vandenberghe EA. Appleby N, et al. Among authors: hayat a. Leuk Lymphoma. 2018 Jun;59(6):1338-1347. doi: 10.1080/10428194.2017.1376746. Epub 2017 Sep 19. Leuk Lymphoma. 2018. PMID: 28925785 Clinical Trial.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, McKay P, Ebsworth T, Miller J, Shah N, Martinez-Calle N, Bishton M, Everden A, Tucker D, El-Hassad E, Hennessy B, Doherty D, Prideaux S, Faryal R, Hayat A, Keohane C, Marr H, Gibb A, Pocock R, Lambert J, Lacey R, Elmusharaf N, Clifford R, Eyre TA. Rampotas A, et al. Among authors: hayat a. Br J Haematol. 2021 Jul;194(2):365-377. doi: 10.1111/bjh.17513. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33959947
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.
Harrison C, Heidel FH, Vannucchi AM, Kiladjian JJ, Hayat A, Passamonti F, Conneally E, Kindler T, Martino B, Lipka DB, Stefanelli T, Roussou P, Germano D, Ewan J, Ribrag V. Harrison C, et al. Among authors: hayat a. Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug. Hemasphere. 2022. PMID: 35935608 Free PMC article. No abstract available.
431 results